Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes
Language English Country United States Media print
Document type Case Reports, Journal Article
- MeSH
- beta Catenin analysis genetics MeSH
- Biopsy MeSH
- Time Factors MeSH
- Cyclin D1 analysis genetics MeSH
- ErbB Receptors analysis genetics MeSH
- Fatal Outcome MeSH
- Oncogene Proteins, Fusion genetics MeSH
- Immunohistochemistry MeSH
- Carcinoma chemistry genetics secondary therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation MeSH
- DNA Mutational Analysis MeSH
- Cell Transformation, Neoplastic genetics pathology MeSH
- Biomarkers, Tumor analysis genetics MeSH
- Tumor Suppressor Protein p53 genetics MeSH
- Parotid Neoplasms chemistry genetics pathology therapy MeSH
- Prognosis MeSH
- Aged MeSH
- Neoplasm Grading MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- beta Catenin MeSH
- CCND1 protein, human MeSH Browser
- CTNNB1 protein, human MeSH Browser
- Cyclin D1 MeSH
- EGFR protein, human MeSH Browser
- ErbB Receptors MeSH
- ETV6-NTRK3 fusion protein, human MeSH Browser
- Oncogene Proteins, Fusion MeSH
- Biomarkers, Tumor MeSH
- Tumor Suppressor Protein p53 MeSH
- TP53 protein, human MeSH Browser
Mammary analogue secretory carcinoma of salivary gland origin (MASC) is a recently described tumor resembling secretory carcinoma of the breast characterized by strong S-100 protein, mammaglobin, and vimentin immunoexpression and which harbors a t(12;15) (p13;q25) translocation resulting in ETV6-NTRK3 fusion product. Histologically, conventional MASC displays bland histomorphology and a lobulated growth pattern and is often composed of microcystic, tubular, and solid structures with abundant eosinophilic homogenous or bubbly secretions. Colloid-like secretory material stains positively for periodic acid-Schiff with and without diastase as well as for Alcian Blue. We present for the first time, 3 patients with MASC of the parotid gland in which high-grade (HG) transformation developed in each case characterized by an accelerated clinical course and poor outcome. The HG component revealed strong membrane staining for EGFR and β-catenin, cytoplasmic/nuclear staining for S-100 protein, and nuclear staining for cyclin-D1, whereas HER-2/neu was absent. Analysis for the presence of the ETV6-NTRK3 fusion transcript revealed positivity in both HG and low-grade component of MASC in 2 of the 3 studied cases. The tumor in case 2 was negative in both its elements for the t(12;15) translocation, but ETV6 gene rearrangement was detected in both components in all 3 cases. Analysis of TP53 and CTNNB1 gene mutations in the HG component of MASCs as well as detection of copy number aberration of EGFR and CCND1 gene did not harbor any abnormalities. All 3 patients with HG-transformed MASC died of disseminated disease within 2 to 6 years after diagnosis. Recognizing HG-transformed MASC and testing for ETV6 rearrangement may be of potential value in patient treatment, because the presence of the ETV6-NTRK3 translocation may represent a therapeutic target in MASC.
References provided by Crossref.org
Molecular pathology in diagnosis and prognostication of head and neck tumors
Newly described salivary gland tumors